Objective: My aim was to examine the ethical, social and legal implications of pharmacogenomics. Method: I performed a critical review of the literature. The primary focal point is the bioethical principle discussed. The second outcome measure is the perspective of the discussion. Results: This review documents that the pharmacogenomics issues of concern are comparable to issues concerning other genetic developments in general. However, two main issues are particular to the case of pharmacogenomics. Firstly, this review reveals that society, industry, groups and individuals appreciate the prospect of pharmacogenomics very differently. Secondly, there is a lack of research into the post-marketing implications of pharmacogenomics. Conclusion: An extensive focus on the ethical, social and legal implications of pharmacogenomics, in terms of both pre- as well as post-marketing issues, is essential. Also, a multidisciplinary approach which includes individual and group opinions in an upfront manner in the research and development process is essential. Otherwise, there is a substantial risk that the positive prospects of pharmacogenomics will not survive due to fear and a lack of acceptance and understanding on the part of the general public.

Keywords:
Pharmacogenomics, Pharmacogenetics, Genomics, Ethics, Bioethics, Drugs, Social implications, Legal implications
1.
Maynard SJ: The Theory of Evolution. Baltimore, Penguin, 1962.
2.
Evans WE, Relling MV: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999;286:5439–5491.
3.
Nebert DW: Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist? Clin Genet 1999;56:247–258.
4.
Motulsky AG: Drug reactions, enzymes and biochemical genetics. JAMA 1957;165:835–836.
5.
Vogel F: Moderne Probleme der Humangenetik. Ergeb Inn Med Kinderheilkd 1959;12:52–125.
6.
Rioux PP: Clinical trials in pharmacogenetics and pharmacogenomics: Methods and applications. Am J Health Syst Pharm 2000;57:887–901.
7.
Wallace RW: Pharmacogenomics: The next logical step. Drug Discov Today 1999;4:105–107.
8.
Kalow W: Pharmacogenetics – Heredity and the Response to Drugs. Philadelphia, Saunders, 1962.
9.
Vesell ES: Twin studies in pharmacogenetics. Hum Genet Suppl 1978;1:19–30.
10.
Meyer UA: Pharmacogenetics: The slow, the rapid, and the ultrarapid. Proc Natl Acad Sci USA 1994;91:1983–1984.
11.
Bell J, Taylor J: Pharmacogenomics: A New Approach to Targeting Therapies. Richmond, PJB, 1998.
12.
Grahame-Smith DG: How will knowledge of the human genome affect drug therapy? Br J Clin Pharmacol 1999;47:7–10.
13.
Bailey DS, Bondar A, Furness LM: Pharmacogenomics – it’s not just pharmacogenetics. Curr Opin Biotechnol 1998;9:595–601.
14.
Snedden R: The challenge of pharmacogenetics and pharmacogenomics. New Genet Soc 2000;19:145–164.
15.
Bell J: The new genetics in clinical practice. BMJ 1998;316:618–620.
16.
Drews J: Genomic sciences and the medicine of tomorrow. Nat Biotechnol 1996;14:1516–1519.
17.
Drews J: Intent and coincidence in pharmaceutical discovery. Drug Made Ger 1995;3:81–86.
18.
Krynetski EY, Evans WE: Pharmacogenetics of cancer therapy: Getting personal. Am J Hum Genet 1998;63:1–7.
19.
Lehman Brothers: Pharmaceutical Company Valuation. New York, Lehman Brothers, 1997.
20.
Haseltine WA: The case for gene patents. Technol Rev 2000;103:59.
21.
Peakman T, Arlington S: Putting the code to work: The promise of pharmacogenetics and pharmacogenomics. Drug Discov World 2001;2:35–40.
22.
DiMasi JA: Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995;58:1–14.
23.
Moran M: Taking it personally. Am Med News 1998;41:37–38.
24.
King J: Opportunities abound in pharmacogenomics. Scientist 1999;13:16–18.
25.
Anderson WH, Fitzgerald CQ, Manasco PK: Current and future applications of pharmacogenomics. New Horiz Sci Pract Acute Med 1999;7:262–269.
26.
Meek J: Development of gene test drugs pose ethics dilemma. The Guardian, April 14, 2000.
27.
Wolf CR, Smith G, Smith RL: Science, medicine, and the future: Pharmacogenetics. BMJ 2000;320:987–990.
28.
Adam GI, Reneland R, Andersson M, Risinger C, Nilsson M, Lewander T: Pharmacogenomics to predict drug response. Pharmacogenomics 2000;1:5–14.
29.
Vesell ES: Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 2000;40:930–938.
30.
Weber WW: Effect of pharmacogenetics on medicine. Environ Mol Mutagen 2001;37:179–184.
31.
Weber WW: The legacy of pharmacogenetics and potential applications. Mutat Res 2001;479:1–18.
32.
Spear BB, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol Med 2001;7:201–204.
33.
Meisel C, Roots I, Cascorbi I, Brinkmann U, Brockmoller J: How to manage individualized drug therapy: Application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med 2000;38:869–876.
34.
Marshall A: Getting the right drug into the right patient. Nat Biotechnol 1997;15:1249–1252.
35.
Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667–1671.
36.
Pfost DR, Boyce-Jacino MT, Grant DM: A SNPshot: Pharmacogenetics and the future of drug therapy. Trends Biotechnol 2000;18:334–338.
37.
Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM: Impact of genomics on drug discovery and clinical medicine. QJM 2000;93:391–423.
38.
Kendall P: Breaking the code: Issues in ethics, law, and society resulting from genetic research. Disability Policy Consortium 2000;1–15.
39.
Middleton L, Freeman A, Brewster S, Foster C, Roses A: From gene-specific tests to pharmacogenetics. Community Genet 2000;3:198–203.
40.
Meslin EM, Thomson EJ, Boyer JT: The Ethical, Legal, and Social Implications Research Program at the National Human Genome Research Institute. Kennedy Inst Ethics J 1997;7:291–298.
41.
Marshall E: The genome program’s conscience. Science 1996;274:488–490.
42.
Sharp RR, Barrett JC: The environmental genome project: Ethical, legal and social implications. Environ Health Perspect 2000;4:279–281.
43.
Sharp RR, Barrett JC: The Environmental Genome Project and Bioethics. Kennedy Inst Ethics J 1999;9:175–188.
44.
Beauchamp TL, Childress JF: Principles of Biomedical Ethics, ed 4. Oxford, Oxford University Press, 1994.
45.
Beauchamp TL, Walters L: Contemporary Issues in Bioethics, ed 5. Belmont, Wadsworth, 1999.
46.
Rescher N: Distributive Justice. Indianapolis, Bobbs-Merrill, 1966.
47.
Det etiske råd: Prioritering inden for Sundhedsvæsnet. København, Det etiske råd, 2001.
48.
Kappel K: Hvordan kan man diskutere bioetiske problemer?; in Jensen KK, Andersen S (eds): Bioetik. København, Rosinante, 1999, pp 199–239.
49.
Jones AH: Literature and medicine: Narrative ethics. Lancet 1997;349:1243–1246.
50.
Cahill LS: The new biotech world order. Hastings Cent Rep 1999;29:45–48.
51.
Cahill LS: The Catholic tradition: Religion, morality, and the common good. J Law Relig 1987;5:75–94.
52.
Vicini A: The use of genetic information: Autonomy and the common good. Intellect Prop Technol Forum 1999;060508:1–11.
53.
Grant SFA: Pharmacogenetics and pharmacogenomics: Tailored drug therapy for the 21st century. Trends Pharmacol Sci 2001;22:3–4.
54.
Coons SJ: Pharmacogenomics: Here it comes, ready or not. Clin Ther 2001;23:274–275.
55.
Elmer-DeWitt P: The future of drugs. Time 2001;157:56–57.
56.
Ingelman-Sundberg M: Pharmacogenetics: An opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001;250:186–200.
57.
Kleeberg U, Frotschl R: Pharmakogenetik und Polymorphismen – Chance für eine individuelle Pharmakotherapie? Klinikarzt 2001;30:43–48.
58.
Engel GL: The clinical application of the biopsychosocial model. Am J Psychiatry 1977;137:535–544.
59.
Mount JK: Contributions of the social sciences; in Wertheimer AI, Smith MC (eds): Pharmacy Practice: Social and Behavioral Aspects. Baltimore, Williams & Wilkins, 1989, pp 1–22.
60.
Baird PA: Altering human genes: Social, ethical, and legal implications. Perspect Biol Med 1994;37:566–575.
61.
Caplan A: Handle with care: Race, class and genetics; in Murphy TF, Lappé M (eds): Justice and the Human Genome Project. Berkeley, University of California Press, 1994, pp 30–45.
62.
Churchill LR, Collins ML, King NMP, Pemberton SG, Wailoo KA: Genetic research as therapy: Implications of ‘gene therapy’ for informed consent. J Law Med Ethics 1998;26:38–47.
63.
Fletcher JC: The ethics of human gene therapy. N Engl J Med 1997;336:1843–1844.
64.
Goodman KW: Ethics, genomics and information retrieval. Comput Biol Med 1996;26:223–229.
65.
Graham JB: Ethical and social issues posed by genetic studies of cardiovascular disease. Perspect Biol Med 1997;20:260–270.
66.
Grisham JL: Genetic testing challenges. Chem Eng News 1999;77:29–32.
67.
Group of Advisers on the Ethical Implications of Biotechnology. The ethical implications of gene therapy. Politics Life Sciences 1995;14:267–268.
68.
Gulcher JR, Stefansson K: Ethics of population genomics research. Nature 1999;400:307–308.
69.
Hudson K, Rothenberg K, Andrews L, Kahn M, Collins F: Genetic discrimination and health insurance: An urgent need for reform. Science 1995;270:391–393.
70.
Jackson F: Scientific limitations and ethical ramifications of a non-representative Human Genome Project: African American response. Sci Eng Ethics 1998;4:155–170.
71.
Juengst ET: Caught in the middle again: Professional ethical considerations in genetic testing for health risks. Genet Test 1998;1:189–200.
72.
Kolata G: Genetic screening raises questions for employers and insurers. Science 1986;232:317–319.
73.
Lapham EV, Kozma C, Weiss J: Genetic discrimination: Perspectives of consumers. Science 1996;274:621–624.
74.
Lemmens T, Poupak B: Genetics in life, disability and additional health insurance in Canada: A comparative legal and ethical analysis; in Knoppers B (ed): Socio-Ethical Issues in Human Genetics. Cowansville, Yvon Blais, 1998, pp 107–275.
75.
Lisagor M: Gene patents: Jarring, but legally sound. Natl J 2000;32:2316–2317.
76.
Patterson WP: Technology and ethics: Genetic screening. Industry Week 1997;233:45–50.
77.
Ploos van Amstel JK, van Haeften TW, Giltay JC: Genetics in medical practice after 2000 (in Dutch). Ned Tijdschr Geneeskd 1999;143:2261–2265.
78.
Rothstein M: Genetic Discrimination in Employment and the Americans White Disabilities Act. Houst Law Rev 1992;29:23–85.
79.
Shulman S: Toward sharing the genome. Technol Rev 2000;103:60–67.
80.
Solicitor General Canada: Human Genome Workshop. Ottawa, Department of the Solicitor General Canada, Health Canada, and The Department of Justice, 2000.
81.
Takala T, Gylling HA: Who should know about our genetic makeup and why? J Med Ethics 2000;26:171–174.
82.
Thomas SM: Genomics and intellectual property rights. Drug Discov Today 1999;4:134–138.
83.
Thomas SN: Genomics: The implications for ethics and education. Br Med Bull 1999;55:439–445.
84.
Stokes R: Genomics and economics. Pharm Technol Eur 2000;12:54–55.
85.
Low L, King S, Wilkie T: Genetic discrimination in life insurance: Empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom. BMJ 1998;317:1632–1635.
86.
Beardsley T: Vital data. Sci Am 1996;3:76–81.
87.
Bobrow M, Thomas S: Patents in a genetic age. Nature 2001;409:763–764.
88.
Kadens DT, Le-Gear-Michele L: Pharmacogenomics: Into the new millennium. Drug Dev Res 2000;49:17–21.
89.
Moos WH, Steliou K: Pharmacogenomics 2000. Drug Dev Res 2000;49:1–3.
90.
Genetic Interest Group: Guidelines for Genetic Services. London, Genetic Interest Group, 2000.
91.
Levitt M: The ethics and impact on behaviour of knowledge about one’s own genome. Interview by Judy Jones. BMJ 1999;319:1283.
92.
Fears R, Roberts D, Poste G: Rational or rationed medicine? The promise of genetics for improved clinical practice. BMJ 2000;320:933–935.
93.
Hinde A: Evolution, not revolution. Trends Biotechnol 2000;18:230–231.
94.
Richards T: The genomic challenge – it is huge and the NHS is poorly prepared to meet it. BMJ 1999;318:341–342.
95.
Issa AM: Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol Sci 2000;21:247–249.
96.
Shah RR: Regulatory aspects of integration of pharmacogenetics into drug development. Int J Pharm Med 2001;15:67–69.
97.
Møldrup C: Farmakogenetikkens betydning for den primære sundhedssektor. Ugeskr Læger, in press.
98.
Peltonen L, McKusick VA: Dissecting human disease in the postgenomic era. Science 2001;291:1224–1229.
99.
Fears R, Weatherall D, Poste G: The impact of genetics on medical education and training. Br Med Bull 1999;55:460–470.
100.
Chi J: Gene therapy is coming: Is your pharmacy ready? Drug Topics 2000;144:24.
101.
Jaggers LD: Pharmacogenomics: Worthy of pharmacy’s attention. Am J Health Syst Pharm 1999;56:27.
102.
Carrico JM: Human Genome Project and pharmacogenomics – implications for pharmacy. J Am Pharm Assoc (Wash) 2000;40:115–116.
103.
Lemonick MD: Brave new pharmacy. Time 2001;157:58–66, 69.
104.
Stripp D: A DNA tragedy. Fortune 2001;142:170–184.
105.
Modell M, Wonke B, Anionwu E, Khan M, Tai SS, Lloyd M, Modell B: A multidisciplinary approach for improving services in primary care: Randomised controlled trial of screening for haemoglobin disorders. BMJ 1998;317:788–791.
106.
McCarthy A: Pharmacogenetics: Industry and academic researchers must collaborate to deliver its benefits. BMJ 2001;322:1007–1008.
107.
Mehl B, Santell JP: Projecting future drug expenditures – 2000. Am J Health Syst Pharm 2000;57:129–138.
108.
Carey J: This drug is for you. Bus Week 1999;3612:98–100.
109.
Rothstein MA, Epps PG: Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001;2:228–231.
110.
Edlin G: Inappropriate use of genetic terminology in medical research: A public health issue. Perspect Biol Med 1987;31:47–56.
111.
Schmidt K: Just for you: One person’s cure can be somebody else’s poison. To find out which drug is right for you, doctors may soon turn to genetic testing. New Scientist 1998;(160):32–36.
112.
Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200–1205.
113.
Pass KA: Pharmacogenetics and public health: A good match. Genet Med 2001;3:227.
114.
Ross JS: The impact of molecular diagnostic tests on patient outcomes. Clin Lab Med 1999;19:815–831.
115.
Housman D, Ledley FD: Why pharmacogenomics? Why now? Nat Biotechnol 1998;16:492–493.
116.
Schulman KA, Linas BP: Pharmacoeconomics: State of the art. Annu Rev Public Health 1997;18:529–548.
117.
Foot E, Bieber F, Kroll W, Sagnier PP, Waltl G, Zuehlsdorf M, et al: Impact of pharmacogenetics on health care and health economics. Int J Pharm Med 2001;15:95–100.
118.
Foster MW, Sharp RR, Mulvihill JJ: Pharmacogenetics, race, and ethnicity: Social identities and individualized medical care. Ther Drug Monit 2001;23:232–238.
119.
Knoppers B, Chadwick R, Takebe H, Berg K, Cantu JM, Daar AS, et al: HUGO urges genetic benefit sharing. Community Genet 2001;3:88–92.
120.
Knoppers B: Pharmacogenomics, patients and profits. Eur J Hum Genet 2000;8(suppl).
121.
Arledge T, Freeman A, Arbuckle J, Mosteller M, Manasco P: Applications of pharmacogenetics to drug development: The Glaxo Wellcome experience. Drug Metab Rev 2000;32:387–394.
122.
Hodgson J, Marshall A: Pharmacogenomics: Will the regulators approve? Regulatory agencies face new challenges with the advent of drugs targeted at subgroups of the population. Nat Biotechnol 1998;16:243–246.
123.
Regalado A: Inventing the pharmacogenomics business. Am J Health Syst Pharm 1999;56:40–50.
124.
Weijer CW: Selecting subjects for participation in clinical research: One sphere of justice. J Med Ethics 1999;25:31–36.
125.
Marinker M: Looking and leaping; in Marinker M, Peckhan MM (eds): Clinical Futures. London, BMJ, 1998, pp 1–19.
126.
Coats JS: Pharmacogenomics: Hope or hype? Int J Cardiol 2000;76:1–3.
127.
Drug companies’ target practice. Economist 1997;345:66–67.
128.
Chustecka Z: The impact of genomics on drug discovery. Scrip 1998;2325:22–23.
129.
Fijal BA, Hall JM, Witte JS: Clinical trials in the genomic era: Effects of protective genotypes on sample size and duration of trial. Control Clin Trials 2000;21:7–20.
130.
Shi MM, Bleavins MR, de la Iglesia FA: Pharmacogenetic application in drug development and clinical trials. Drug Metab Dispos 2001;29:591–595.
131.
Moyses C: Pharmacogenetics, genomics, proteomics: The new frontiers in drug development. Int J Pharm Med 1999;13:197–202.
132.
Kuhlmann J: Alternative strategies in drug development: Clinical pharmacological aspects. Int J Clin Pharm Ther 1999;37:575–583.
133.
Kurth JH: Pharmacogenomics: Future promise of a tool for identifying patients at risk. Drug Inf J 2000;34:223–227.
134.
Ozdemir V, Shear NH, Kalow W: What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Saf 2001;24:75–85.
135.
Chamberlain JC, Joubert PH: Opportunities and strategies for introducing pharmacogenetics into early drug development. Drug Discov Today 2001;6:569–574.
136.
Carr G: The alchemists – a survey of the pharmaceutical industry. Economist 1998, Feb 21, pp 1–18.
137.
Roses AD: Pharmacogenetics: A disruptive technology for the next decade (abstract). Eur J Hum Genet 2001;9(suppl 1):61.
138.
Persidis A: Pharmacogenomics and diagnostics. Nat Biotechnol 1998;16:791–792.
139.
Stephenson J: Ethics group drafts guidelines for control of genetic material and information. JAMA 1998;279:184.
140.
Lindpaintner K: Pharmacogenomics: A review of concepts and contents. Drug Discov World 2001;summer:21–25.
141.
Williamson B: Healthy genes in a healthy body. World Health 1998;51:28–29.
142.
Juengst ET: Groups as gatekeepers to genomic research: Conceptually confusing, morally hazardous, and practically useless. Kennedy Inst Ethics J 1998;8:183–200.
143.
Sadee W: Genomics and drugs: Finding the optimal drug for the right patient. Pharm Res 1998;15:959–963.
144.
Maitland-van der Zee AH, de Boer A, Leufkens HGM: The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol 2000;410:121–130.
145.
Foster MW, Sharp RR: Genetic research and culturally specific risks: One size does not fit all. Trends Genet 2000;16:93–95.
146.
Grounds RA: The Yuchi community and the human genome diversity project. Cult Surviv Q 1996;summer:64–68.
147.
Robertson JA: Consent and privacy in pharmacogenetic testing. Nat Genet 2001;28:207–209.
148.
Myers MA: Use of polymorphism analysis required ethical guidelines. BMJ 2000;321:453.
149.
Knudsen LE, Renneberg J: Genetisk testning og deltagelse i kliniske afprovninger af laegemidler. Ugeskr Laeger 1999;161:5038.
150.
Richards M: Patients’ understanding of genetics and attitudes towards genetics. Eur J Hum Genet 2000;8:33.
151.
Marteau T: Communicating genetic risk information (abstract). Eur J Hum Genet 2001;9(suppl 1):70.
152.
Annas GJ: Some Choice: Law, Medicine and the Market. Oxford, Oxford University Press, 2000.
153.
Galton DJ, Ferns GAA: Genetic markers to predict polygenic disease: A new problem for social genetics. QJM 1999;92:223–232.
154.
Sadee W: Pharmacogenomics. BMJ 1999;319:1286–1290.
155.
Lemmens T: ‘What about your genes?’ Ethical, legal, and policy dimensions of genetics in the workplace. Politics Life Sciences 1997;16:57–75.
156.
Hodgkin P: SNPs: Pharmaco-genomics – or why therapeutics is about to get more complicated. Br J Gen Pract 2000;50:255.
157.
Jones S: Genetics in Medicine: Real Promises, Unreal Expectations: One Scientist’s Advice to Policymakers in the United Kingdom and the United States. New York, Milbank Memorial Fund, 2000, pp 1–13.
158.
Beck U: Risk Society: Towards a New Modernity. London, SAGE, 1992.
159.
Cohen J: Developing prescriptions with a personal touch. Science 1997;275:776.
160.
Omenn GS: Prospects for pharmacogenetics and ecogenetics in the new millennium. Drug Metab Dispos 2001;29:611–614.
161.
Morrison PJ: Implications of genetic testing for insurance in the UK. Lancet 1998;352:1647–1648.
162.
Bolhuis PA: Het belang van de farmacogenetica. Ned Tijdschr Geneeskd 2001;145:15–18.
163.
Draper E: Risky Business: Genetic Testing and Exclusionary Practices in the Hazardous Workplace. New York, Cambridge University Press, 1991.
164.
Rothenberg K: Genetic information and health insurance: State legislative approaches. J Law Med Ethics 1995;23:312–319.
165.
McEwen J, McCarty K, Reilly PR: A survey of medical directors of life insurance companies concerning use of genetic information. Am J Hum Genet 1993;53:33–45.
166.
McGleenan T: Legal and policy issues in genetics and insurance. Community Genet 2000;3:45–49.
167.
Wolf SM: Beyond genetics discrimination: Towards the broader harm of geneticsm. J Clin Pharmacol 1995;23:345–353.
168.
Zhou HH, Liu ZQ: Ethnic differences in drug metabolism. Clin Chem Lab Med 2000;38:899–903.
169.
Nelkin D, Tancredi L: Dangerous Diagnostics: The Social Power of Biological Information. New York, Basic Books, 1990.
170.
Geller L: Individual, family, and social dimensions of genetic discrimination. Sci Eng Ethics 1996;2:78.
171.
Roses AD: Pharmacogenetics and the practice of medicine. Nature 2000;405:857–865.
172.
Møldrup C: When pharmacogenomics goes public. New Genet Soc, accepted.
173.
Knudsen P, Hansen EH, Morgall JM: From one stigma to another – perceptions of younger women using SSRI antidepressants. Soc Sci Med, submitted.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.